Chimeric antigen receptors with CD20 safety switch
AssigneeSt. Jude Children's Research Hospital
InventorsMireya Paulina Velasquez, Stephen Gottschalk, Janice Riberdy, Albert Zhou, Byoung Ryu, Abishek Vaidya, Giedre Krenciute
Life of this patent
Estimating the term…
Abstract
The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have enhanced antitumor properties and/or can be regulated by safety switches. Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a cancer in a subject are also provided.
Claims15
A polynucleotide encoding a chimeric antigen receptor (CAR) comprising:
- (a) a leader sequence derived from CD8α,
- (b) an anti-CD123 single chain variable fragment (scFv) comprising (i) the nucleotide sequence of SEQ ID NO:
- 30 encoding scFV (292) or (ii) the nucleotide sequence of SEQ ID NO:
- 32 encoding scFV (716),
- (c) a hinge domain derived from CD28,
- (d) a transmembrane domain derived from CD28, and
- (e) a cytoplasmic domain comprising (i) a costimulatory domain derived from CD28 and (ii) a signaling domain derived from CD3ζ.
Dependencies are inferred from the claim text.